Lidocaine is a well known topical local anaesthetic used for a wide variety of ailments, including temporary relief of rashes, stings, sprains, strains, bites and burns. However, it has poor penetration into the dermis, frequently rendering it largely ineffective. Global sales of topical local anesthetics in 2007 were USD 1.2 billion.
Lidocaine is sold in many forms. It is available as an ointment, jelly, patch or aerosol for topical use, as an oral solution, and as an injection for local anaesthesia.
Phosphagenics’ proven pharmaceutical delivery technology, TPM®, can be used as a targeted, localised delivery system, to increase the delivery of actives such as lidocaine to targeted areas while minimising exposure to the rest of the body.
Phosphagenics’ TPM/lidocaine formulation is capable of improving the penetration rate and delivery concentration of lidocaine while, importantly, limiting systemic exposure.
Phosphagenics’ TPM/lidocaine successfully completed a Phase 1 human clinical trial in 2008. This trial demonstrated that Phosphagenics’ TPM® delivery system is able to increase both the depth of delivery of lidocaine and the amount of lidocaine delivered into skin compared to a leading marketed preparation.